trial

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

NCTId NCT00725855
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 12 (estimated)
Sponsored by Memory Pharmaceuticals
Primary completion 2009-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
12 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2008-08
Primary completion
2009-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
MEM 3454

Sponsors

Memory PharmaceuticalsLead Sponsor
Hoffmann-La RocheCollaborator

Sites

1 total
Denver, United States

Linked catalysts

1
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and M — primary completion2009-03

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE2
Primary Completion Date
2009-03
Status
UNKNOWN
relationships
The graph out of here
drug
MEM 3454
drug
lead_sponsor
Memory Pharmaceuticals
company
collaborator
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication